Bradley D. Kwinta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bradley D. Kwinta has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Larisa J. Geskin
Department of Dermatology, Columbia University, New York, NY 10032, USA
2 shared publications - Amir Reza Djavid
A.R. Djavid, MD, Department of Dermatology, Columbia University, Vagelos College of Physicians and Surgeons, New York, New York, USA
1 shared publication - Anuk Burli
Stanford University School of Medicine
1 shared publication - Benjamin T. Fullerton
Department of Neurology, Columbia University
1 shared publication - Chavy Chiang
University of Rochester Medical Center
1 shared publication - Christina Huang
Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania
1 shared publication
Latest Publications
- 22 November 2025
- Published by Springer Nature
- p. 361-381
Topical Antineoplastics in Dermatology
- Open Access
Etiologies of Melanoma Development and Prevention Measures: A Review of the Current Evidence
(1) Melanoma is the most aggressive dermatologic malignancy, with an estimated 106,110 new cases to be diagnosed in 2021. The annual incidence rates continue to climb, which underscores the critical importance of improving the methods to prevent this disease. The interventions to assist with melanoma prevention vary and typically include measures such as UV avoidance and the use of protective clothing, sunscreen, and other chemopreventive agents. However, the evidence is mixed surrounding the use of these and other interventions. This review discusses the heritable etiologies underlying melanoma development before delving into the data surrounding the preventive methods highlighted above. (2) A comprehensive literature review was performed to identify the clinical trials, observational studies, and meta-analyses pertinent to melanoma prevention and incidence. Online resources were queried to identify epidemiologic and clinical trial information. (3) Evidence exists to support population-wide screening programs, the proper use of sunscreen, and community-targeted measures in the prevention of melanoma. Clinical evidence for the majority of the proposed preventive chemotherapeutics is presently minimal but continues to evolve. (4) Further study of these chemotherapeutics, as well as improvement of techniques in artificial intelligence and imaging techniques for melanoma screening, is warranted for continued improvement of melanoma prevention.
Open AccessEtiologies of Melanoma Development and Prevention Measures: A Review of the Current Evidence
(1) Melanoma is the most aggressive dermatologic malignancy, with an estimated 106,110 new cases to be diagnosed in 2021. The annual incidence rates continue to climb, which underscores the critical importance of improving the methods to prevent this disease. The interventions to assist with melanoma prevention vary and typically include measures such as UV avoidance and the use of protective clothing, sunscreen, and other chemopreventive agents. However, the evidence is mixed surrounding the use of these and other interventions. This review discusses the heritable etiologies underlying melanoma development before delving into the data surrounding the preventive methods highlighted above. (2) A comprehensive literature review was performed to identify the clinical trials, observational studies, and meta-analyses pertinent to melanoma prevention and incidence. Online resources were queried to identify epidemiologic and clinical trial information. (3) Evidence exists to support population-wide screening programs, the proper use of sunscreen, and community-targeted measures in the prevention of melanoma. Clinical evidence for the majority of the proposed preventive chemotherapeutics is presently minimal but continues to evolve. (4) Further study of these chemotherapeutics, as well as improvement of techniques in artificial intelligence and imaging techniques for melanoma screening, is warranted for continued improvement of melanoma prevention.